• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Lupin launches authorised generic version of Apriso

expresspharmaMay 19, 2020

Tag: mesalamine , ulcerative colitis , lupin , Apriso

Mesalamine Extended-Release Capsules 0.375 g (the authorized generic version) are indicated for the maintenance of remission of ulcerative colitis in patients 18 years of age and older.

Pharma major Lupin announced the launch of authorized generic version of Bausch Health’s Apriso (Mesalamine Extended-Release Capsules 0.375 g) in the U.S.

Mesalamine Extended-Release Capsules 0.375 g (authorized generic version) are indicated for the maintenance of remission of ulcerative colitis in patients 18 years of age and older.

Mesalamine Extended-Release Capsules 0.375 g. Apriso had an annual sales of approximately USD 290 million in the US (IQVIA MAT March 2020).


Previous:AZ/Daiichi Sankyo's Enhertu picks up third breakthrough designation

Next:Ashwagandha can be effective preventive drug against coronavirus: IIT Delhi research

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Lupin launches authorised generic version of Apriso | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Lupeol-98%-Lupinus Albus Extracts

Lupeol-98%-Lupinus Albus Extracts
Mesalamine Impurity 4

Mesalamine Impurity 4
Mesalamine Impurity N (5-Nitrosalicylic Acid)

Mesalamine Impurity N (5-Nitrosalicylic Acid)
Lupeol-8%-Lupinus Albus Extracts

Lupeol-8%-Lupinus Albus Extracts
Mesalamine Impurity D

Mesalamine Impurity D
Mesalamine

Mesalamine
Mesalamine

Mesalamine
PHENOXYMETHYL PENICILLIN POTASSIUM

PHENOXYMETHYL PENICILLIN POTASSIUM
LINCOMYCIN HCL

LINCOMYCIN HCL
GENTAMYCIN SULPHATE macrolides

GENTAMYCIN SULPHATE macrolides

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service